QED-701
Neuroinflammatory diseases (e.g., multiple sclerosis)
PreclinicalActive
Key Facts
Indication
Neuroinflammatory diseases (e.g., multiple sclerosis)
Phase
Preclinical
Status
Active
Company
About Lucia Bio
Australian‑focused biotech creating next‑generation oral Syk inhibitors for autoimmune, neuroinflammatory and oncology markets.
View full company profile